University of British Columbia Okanagan Campus
Kelowna, British Columbia, V1V1V7, Canada
Location status: Recruiting
NCT Number: NCT06590623
To conduct a single-arm pilot study to determine how acute ingestion of an exogenous ketone monoester supplement alters the histone lysine β-hydroxybutyrylation and immune function in healthy human monocytes and lymphocytes.
Interested in participating?
Request Info19 year and older
All sexes
Interventional
Not applicable
Kelowna, British Columbia, V1V1V7, Canada
Location status: Recruiting
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Participants will receive an exogenous ketone supplement (KetoneAid KE4) in a fasted state in the morning, at a dosage of 0.75 g/kg of body weight.
Other names: Exogenous ketone
Time frame: Before (fasted state) and 2 hours after the consumption of the exogenous ketone supplement.
The β-hydroxybutyrylation of histones in human monocytes and lymphocytes will be assessed before and 2 hours after the consumption of an exogenous ketone supplement. Protein samples will be collected from the cells, and the levels of histone β-hydroxybutyrylation will be quantified using Western blotting.
Time frame: Capillary beta-hydroxybutyrate will be measured before, 30, 60, 90, 120 and 180 minutes after the consumption of exogenous ketone supplement.
Capillary beta-hydroxybutyrate concentration will be measured using FreeStyle Neo β ketone test before, 30, 60, 90, 120, and 180 minutes after the consumption of exogenous ketone supplement.
Time frame: Capillary glucose concentration will be measured before, 30, 60, 90, 120, and 180 minutes after the consumption of exogenous ketone supplement.
Capillary glucose concentration will be measured using FreeStyle Neo glucose test before, 30, 60, 90, 120, and 180 minutes after the consumption of exogenous ketone supplement.
Time frame: Before, 30, 60, 90, 120 and 180 minutes after the consumption of the exogenous ketone supplement.
Systolic and diastolic blood pressure will be measured using an automatic blood pressure device before, and at 30, 60, 90, 120, and 180 minutes after consuming the exogenous ketone supplement.
Time frame: Before, 30, 60, 90, 120 and 180 minutes after the consumption of the exogenous ketone supplement.
Resting heart rate will be measured using continuous heart rate measurement (POLAR H10) before, and at 30, 60, 90, 120, and 180 minutes after consuming the exogenous ketone supplement.
Time frame: Before (fasted state) and 2 hours after the consumption of the exogenous ketone supplement.
Immune cell functions in healthy individuals will be assessed using whole blood and monocyte cultures treated with lipopolysaccharide (with or without interleukin-10) and the subsequent measurement of cytokine secretion (e.g., TNF-a), both before and 2 hours after the ingestion of a ketone supplement.
Time frame: Before (fasted state) and 2 hours after the consumption of the exogenous ketone supplement.
Immunophenotyping of monocytes and lymphocytes will be conducted by assessing surface receptor expression using flow cytometry. Various antibodies will be used, including CD14, CD16, and TLR4 for monocytes, and CD4 and CD8 for lymphocytes, at baseline and 2 hours following the ingestion of a ketone supplement.
Time frame: Before, and at 30, 60, 90, 120, and 180 minutes after consuming the exogenous ketone supplement.
Gastrointestinal disturbance will be measured using a 10-cm visual analogue scale to assess nausea, urge to vomit, bloating, belching, and cramps before, and at 30, 60, 90, 120, and 180 minutes after consuming the exogenous ketone supplement. A higher score, closer to the right end of the 10-cm visual analogue scale, indicates greater gastrointestinal disturbance.
Contact information is provided by the study sponsor or research team.
Jonathan Little Principal Investigator, Professor Little, Ph.D
CONTACT
University of British Columbia
Other
Acronym: Acute_Ketone
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06195982
Acid-Base Imbalance, Acidosis
Durham, North Carolina, United States
View Trial DetailsNCT07218497
Acid-Base Imbalance, Acidosis
Los Angeles, California, United States
View Trial DetailsNCT06937320
Acid-Base Imbalance, Acidosis
Durham, North Carolina, United States
View Trial DetailsNCT06472427
Acid-Base Imbalance, Acidosis
Leuven, Vlaams-Brabant, Belgium
View Trial Details